# CD86 (B7-2)

Source: https://onco.cc/targets/cd86/  
OnCo record `cd86` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CD86 is one of the two B7 molecules on antigen-presenting cells that either wake a T cell up (through CD28) or calm it down (through CTLA-4). Ipilimumab works by stopping CTLA-4 from hogging CD86 and CD80.

## Summary

CD86 (chromosome 3q13.33) is a costimulatory molecule of the immunoglobulin superfamily on the surface of antigen-presenting cells that acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T cells by binding the constitutively expressed CD28 receptor (UniProt P42081). CTLA-4 binds CD80 and CD86 with considerably stronger affinity than CD28 does and acts as a decoy receptor (UniProt P16410), which is the interaction anti-CTLA-4 antibodies release.

## Fields

- Kind: Target
- Last checked: 2026-09-24
- Also known as: B7-2; B7.2; CD28LG2; CD86 molecule
- Tags: checkpoint-map
- Symbol: CD86
- Class: checkpoint
- Biology: Shares the CD28/CTLA-4 ligand role with CD80; no drug in the corpus binds CD86 directly.
- Where found: Antigen-presenting cells (UniProt P42081)

## Notes

- Prevalence not recorded: HGNC and UniProt carry no positivity rates.

## Sources

- HGNC HGNC:1705: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1705
- UniProt P42081: https://www.uniprot.org/uniprotkb/P42081/entry
- NCBI Gene 942: https://www.ncbi.nlm.nih.gov/gene/942

## Connected records

- targets: [CD28](https://onco.cc/targets/cd28/), [CD80 (B7-1)](https://onco.cc/targets/cd80/), [CTLA-4](https://onco.cc/targets/ctla4/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/)
- pathways: [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)
- terms: [Checkpoint (two meanings)](https://onco.cc/terms/checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/cd86.json